X Facebook LinkedIn WhatsApp Press Releases (-) Any 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2018 March 25, 2018 argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe March 21, 2018 argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases March 15, 2018 argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies March 5, 2018 argenx to Present at Cowen & Company 38th Annual Health Care Conference February 28, 2018 argenx reports fourth quarter business update and full year 2017 financial results February 21, 2018 argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018 2017 December 17, 2017 argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million December 13, 2017 argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering December 12, 2017 argenx announces size of proposed public offering in the United States updated to 3.5 million ADSs December 10, 2017 argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis December 10, 2017 argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting December 10, 2017 argenx announces launch of proposed public offering in the United States Pagination First page « First Previous page ‹ Previous … Page 15 Page 16 Page 17 Page 18 Current page 19 Page 20 Page 21 Page 22 Page 23 … Next page Next › Last page Last »